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Abstract
Introduction:  Hemophagocytic  syndrome,  macrophage  activation  syndrome,  reactive  histiocy-
tosis or  hemophagocytic  lymphohistiocytosis  (HLH)  represent  a  group  of  diseases  whose  common
thread is  reactive  or  neoplastic  mononuclear  phagocytic  system  cells  and  dendritic  cell  prolif-
eration.
Clinical case:  We  present  a  case  of  an  HLH  probably  associated  with  Epstein-Barr  virus  (EBV)  in  a
4-year-old  male  patient  treated  with  HLH-04  protocol.  Viral  etiology  in  HLH  is  well  accepted.  In
this case,  clinical  picture  of  HLH  was  assumed  secondary  to  EBV  infection  because  IgM  serology
at the  time  of  clinical  presentation  was  the  only  positive  factor  in  the  viral  panel.
Conclusions:  Diagnosis  of  HLH  is  the  critical  ﬁrst  step  to  successful  treatment.  The  earlier  it  is
identiﬁed, the  less  the  tissue  damage  and  reduced  risk  of  multiple  organ  failure,  which  favors
treatment  response.
© 2016  Hospital  Infantil  de  México  Federico  Gómez.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).∗ Corresponding author.
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Linfohistiocitosis  hemofagocítica  asociada  con  el  virus  de  Epstein-Barr:  respuesta  al
tratamiento  con  el  protocolo  HLH-04
Resumen
Introducción:  El  síndrome  hemofagocítico,  síndrome  de  activación  de  macrófagos,  histiocitosis
reactiva o  linfohistiocitosis  hemofagocítica  (HLH)  representan  un  grupo  de  enfermedades  cuyo
factor común  es  la  proliferación  reactiva  o  neoplásica  de  las  células  mononucleares  fagocíticas
y del  sistema  de  células  dendríticas.
Caso  clínico: Se  presenta  un  caso  de  HLH  sugestivo  de  tener  una  asociación  con  el  virus  del
Epstein Barr  (VEB)  de  un  paciente  masculino  de  4  an˜os  de  edad,  tratado  con  el  protocolo  HLH-
04. La  etiología  viral  en  HLH  es  reconocida.  En  este  caso  se  asumió  un  cuadro  de  HLH  secundario
a una  infección  por  VEB,  ya  que  la  serología  de  IgM  en  el  momento  de  la  presentación  clínica
fue la  única  positiva  en  el  panel  viral.
Conclusiones:  El  diagnóstico  de  la  HLH  es  el  primer  paso  crítico  para  el  éxito  del  tratamiento.
Entre más  temprano  se  identiﬁque,  existe  menor  dan˜o  tisular  y  menor  riesgo  de  falla  orgánica
múltiple,  lo  que  favorece  la  respuesta  al  tratamiento.
© 2016  Hospital  Infantil  de  México  Federico  Gómez.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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91. Introduction
Hemophagocytic  syndrome,  also  known  as  macrophage  acti-
vation  syndrome,  reactive  histiocytosis  or  hemophagocytic
lymphohistiocytosis  (HLH),  represents  a  group  of  diseases
whose  common  factor  is  reactive  or  neoplastic  prolifera-
tion  of  phagocytic  mononuclear  cells  and  of  the  dendritic
cell  system.1 The  International  Histiocytosis  Society  coined
the  term  to  refer  to  a  genetic  disease  with  severe  systemic
inﬂammation,2 which  occurs  as  the  result  of  a  recessive
genetic  disorder  associated  with  either  defects  in  perforin
or  chromosome  X-linked.  The  disease  affects  the  communi-
cation  of  the  innate  and  adaptive  immune  response,  causing
a  lack  of  removal  of  the  inﬂammatory  cells  harmful  to
the  body  and  that  should  be  removed  once  the  inﬂamma-
tory  process  has  concluded.  It  is  estimated  that  there  are
∼1.2  cases  per  million/year.  These  are  uncommon  cases,
but  its  diagnosis  is  important  because  the  clinical  pictures
are  very  aggressive  and  evolve  in  a  fulminant  manner  and
with  multiple  organ  failure  if  a  precise  and  timely  diagno-
sis  is  not  carried  out.3 In  this  disease,  T  and  B  lymphocyte
count  and  circulating  monocytes  show  normal  values.  How-
ever,  the  defect  is  found  in  the  function  of  T-lymphocytes
and  natural  killer  cells  (NK)  as  well  as  in  the  activation  of
CD4  +  and  CD8  +  T  lymphocytes.4 Other  altered  functions  are
the  response  of  lymphocytes  to  mitogen  activation,  oxida-
tion  of  glucose  in  phagocytes  and,  in  some  cases,  decrease
of  IgA5 antibodies.  Clinical  onset  may  be  spontaneous.  Prior
reports  described  that  ∼17%  of  the  cases  are  associated  with
viral  infections,  among  these,  the  Epstein-Barr  (EBV)  virus.6
This  report  presents  a  case  of  HLH  suggested  to  be  associated
with  EBV.2. Clinical case
We  present  the  case  of  a  4-year-old  male  patient.  The
patient’s  mother  was  33  years  of  age,  healthy  and  denied
e
n
p
dny  drug  addictions.  The  father  was  35  years  of  age  with
 secondary  school  education.  He  was  apparently  healthy
nd  admitted  occasional  smoking.  There  is  an  apparently
ealthy  11-year-old  brother.  The  patient  is  originally  from
nd  resident  of  Ecatepec,  State  of  Mexico.  The  family  lives
n  their  own  home  with  all  urban  services.  Overcrowd-
ng  or  coexistence  with  animals  was  denied.  The  patient
emonstrated  adequate  hygiene  and  dietary  habits.  Vacci-
ation  schedule  was  incomplete  because  there  was  a  lack  of
PT  booster  vaccine.  The  patient  showed  appropriate  psy-
homotor  development  although  he  did  not  attend  any  child
evelopment  center  (Centro  de  Desarrollo  Infantil,  CENDI).
he  patient  was  the  product  of  a  GII  with  regular  prenatal
ontrol  and  the  mother  received  iron  and  folic  acid  intake
rom  the  ﬁrst  trimester  without  complications.  The  patient
as  born  by  cesarean  section  at  39  weeks  of  gestation  due
o  nuchal  cord.  Usual  resuscitation  maneuvers  were  carried
ut.  Apgar  score  was  8/9.  The  infant  cried  and  breathed
t  birth.  Birthweight  was  3150  g  and  length  was  54  cm.  The
nfant  was  discharged  without  complications.
In  March  2014,  the  patient  began  with  right  ear-
che.  He  was  seen  in  consultation  by  a  private  physician.
reatment  with  acetaminophen,  ambroxol  and  amoxicillin
as  prescribed  for  7  days,  without  improvement.  He
lso  began  with  fever  up  to  38.9 ◦C.  Treatment  with
rimethoprim  with  sulfamethoxazole  was  added  due  to
he  persistence  of  fever.  Complete  blood  count  was
one.  Parameters  low  for  age  were  seen  for  hemoglobin,
ematocrit  and  platelets:  hemoglobin  10.5  g/dl  (refer-
nce  value:  11.60-15.30  g/dl),  hematocrit  31.7%  (reference
alue:  35.6-46.52%),  leukocytes  4,920/l  (reference  value:
,290-12400/l),  neutrophils  1082/l (reference  value:
83-3231/l),  bands  27%,  atypical  lymphocytes  5%,  platelets
7,000/l  (reference  value  147-384,000/l).7 Physical
xamination  observed  retroauricular  and  inguinal  lymph
odes,  hepatosplenomegaly,  and  persistent  fever.  The
atient  was  referred  to  hematology  for  study  protocol  with
iagnosis  of  lymphoproliferative  syndrome.
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hFigure  1  (A,B)  Disseminated  erythem
The  patient  was  observed  with  pallor,  adequate  hydra-
ion  and  was  active,  reactive,  and  neurologically  intact
ith  generalized  erythematous  violaceous  rash,  ecchymosis
t  the  venopuncture  sites  (Fig.  1  A  and  1B),  congestive
ropharynx  without  exudate,  and  neck  with  mobile  bilat-
ral  adenomegalies  of  1.5  cm  diameter.  Pulmonary  ﬁelds
ere  well  ventilated  and  he  was  tachycardic.  Abdomen
as  painful  on  deep  palpation,  with  hepatomegaly  at
-5-6  cm  below  the  costal  margin  and  splenomegaly  at  6  cm
nd  inguinal  regions  with  1.5  cm  mobile  adenomegalies.
enitalia  were  consistent  with  age  and  gender  and  extrem-
ties  were  intact  with  3-sec  capillary  reﬁll.  Bone  marrow
spirate  did  not  show  the  presence  of  blasts  and  there  were
bundant  histiocytes  with  hemophagocytosis  (Fig.  2).
The  following  day  the  patient  was  lethargic  with  persis-
ent  fever  up  to  40 ◦C  and  data  of  multiple  organ  failure.
e  subsequently  presented  respiratory  deterioration  that
arranted  endotracheal  intubation  through  rapid  sequence
ntubation  with  cardiac  arrest,  which  reverted  with  a  single
ycle  of  compressions.  He  was  admitted  to  the  Pediatric
ntensive  Care  Unit  (PICU).  The  same  day  he  began  treat-
ent  protocol  HLH-04.8 Brieﬂy,  the  therapy  was  carried  out
uring  the  ﬁrst  8  weeks  with  etoposide,  dexamethasone  and
yclosporin  A,  without  intrathecal  chemotherapy  because
he  cerebral  spinal  ﬂuid  was  acellular  and  clinically  without
eurological  alterations.  He  remained  for  2  days  in  the  PICU
nd  continued  being  managed  in  the  Pediatric  Hematology
c
p
r
t
igure  2  Bone  marrow  aspirate.  Hemodiluted  sample,  without  blas
istiocytes with  hematophagocytosis  are  shown.s  violaceous  rash  and  visceromegalies.
nit  with  satisfactory  progress.  It  is  important  to  mention
hat  care  support  measures  were  very  important;  among
hese,  blood  components  were  all  irradiated  with  white
lood  cells  reduction  ﬁlter.  Two  weeks  later  his  hemato-
ogical  parameters,  liver  function  tests  and  ferritin  were
ormalized  (Tables  1  and  2).  At  the  same  time  the  IgM  EBV-
ositive  serology  was  conﬁrmed  with  a  viral  panel  (Table  3)
s  well  as  changes  in  the  lymphocytic  subpopulations
Table  4).  He  completed  the  treatment  scheme  as  man-
ated  in  the  HLH-04  protocol.7 He  is  currently  disease-free
nd  is  being  followed-up  as  an  outpatient.
. Discussion
athogenesis  of  secondary  HLH  is  unclear  although  it  has
een  associated  with  heterozygocity  or  gene  polymorphisms
s  in  the  familial  HLH.  EBV  has  been  one  of  the  eti-
logic  agents  involved.9 Clinical  manifestations  of  HLH
n  this  patient  correlated  with  what  has  been  previously
eported  and  are  due  to  three  main  causes:  1):  hyperac-
ivation  of  the  T  CD8  +  lymphocytes  and  macrophages;  2)
roliferation,  ectopic  migration  and  inﬁltration  of  these
ells  in  various  organs;  and  3)  hypercytokinemia,  with
ersistently  elevated  levels  of  pro-inﬂammatory  cytokines
esulting  in  progressive  organ  failure  which  can  lead
o  death.9 These  interrelated  factors  lead  to  clinical
ts,  without  foreign  cells  and  with  activated  lymphocytes.  Some
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Table  1  Hematologic  parameters,  hepatic  function  and  ferritin.
Date  Hb  (g/dl)  Leuk/l  TL  TN  Plat/l  LDH
(IU/l)
AST
(IU/l)
ALT
(IU/l)
IB
(mg/dl)
TGL
(mg/dl)
FER
(g/l)
3/25/14  10  4,690  1,700  2,079  69,000  4,447  123  270  7  380  3,500
3/26/14 10  4,430  1,780  2,190  65,000  7,207  378  79  8  420  6,130
3/29/14 8  2,300  1,040  800  10,000  8,900  450  250  9  670  7,230
4/10/14 11  800  500  120  12,000  1,280  250  120  6  420  3,200
5/10/14 10  1,200  1,000  200  20,000  750  78  52  2  128  1,100
6/10/14 12  5,520  2,300  3,200  150,000  250  54  38  0.8  98  500
Hb, hemoglobin; Leuk, leukocytes; TL, total lymphocytes; TN, total neutrophils; Plat, platelets; LDH, lactate dehydrogenase; AST,
aspartate aminotransferase; ALT, alanine aminotransferase; IB, indirect bilirubin; TGL, triglycerides; FER, ferritin.
Table  2  Coagulation  tests.
Date  PT  (s)  (INR*)  APTT  (s)  TT  (s)  FIB  (mg/dl)  D-D  (ng/ml)
3/26/14  18/14  (1.45)  38  25  120  1,200
3/29/14 20/14  (1.70)  46  28  80  3,200
4/10/14 16/14  (1.22)  31  20  220  500
PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; FIB, ﬁbrinogen; D-D, D-dimer; INR, internation-
alized normal ratio (reference values 0.9-1.3).
Table  3  Viral  serology  of  the  patient  at  diagnosis.
Date  HBVs  HBVc  HCV  HIV  EBV  (VCA)
IgG
EBV  (VCA)
IgM
TOXO
IgG/IgM
RB
IgG/IgM
CMV
IgG/IgM
HSV  1  +  2
IgG/IgM
3/29/14  −  −  −  −  +  +  −/−  +/−  −/−  −/−
HBVs, antigen-soluble hepatitis B virus; HBVc, hepatitis B virus antigen core; HCV: hepatitis C virus; HIV, human immunodeﬁciency virus;
EBV, Epstein-Barr virus; VCA, viral capsid antigen; TOXO, toxoplasma; RB, rubeola; CMV, cytomegalovirus; HSV 1 + 2, herpes simplex virus
1 and 2.
Table  4  Subpopulations  of  lymphocytes  and  immunoglobulins.
Date  Leu/l  CD3+  CD4+  CD8+  CD4+/CD8+  NK  NKT  IgA  IgM  IgG
3/30/14  1,540  882  (66%)  454  (34%)  375  (28%)  1.2  41.53  11  193  115  630
Leu, Leucocytes; CD, cluster of differentiation; NK, natural killer; NKT, natural killer T; Ig, Immunoglobulin.
48%);
n
t
p
i
l
o
n
p
g
c
p
sReference values: CD3 + : 900-4500 (43-76%); CD4 + : 500-2300 (23-
5-26%; IgA: 25-154; IgM: 43-196; IgG: 463-1,236.
manifestations  such  as  prolonged  fever,  lymphadenopathy,
hepatosplenomegaly,  bleeding,  skin  rash,  central  nervous
system  abnormalities,  jaundice  and  laboratory  ﬁndings  of
bicytopenia  or  pancytopenia,  coagulopathy,  hyperlipidemia,
hypoﬁbrinogenemia,  hyperferritinemia,  transaminasemia,
hyperbilirubinemia  and  hyponatremia.9
Viral  etiology  in  HLH  is  recognized.  In  this  case  a  picture
of  HLH  secondary  to  an  EBV  infection  was  assumed  because
the  VCA  (viral-capsid  antigen)  serology  IgM  at  the  time
of  the  clinical  presentation  was  the  only  positive  ﬁnding  in
the  viral  panel.  In  addition,  there  are  results  that  place
in  evidence  the  use  of  the  VCA  IgM  marker  in  patients  with
hemophagocytosis  when  the  cut-off  values  of  the  test  are
10sufﬁcient  to  be  considered  positive.
It  was  noted  that  15%  of  patients  with  EBV-associated
HLH  develop  disorders  such  as  selective  hypogammaglobu-
linemia  of  IgA  or  hyper-IgM  syndrome.  Such  syndromes  were
a
r
P
r CD8 + : 300-1600 (14-33%); CD4+/CD8 + : 0.9-2.9; NK: 3.15%; NKT:
ot  observed  in  this  patient  and,  in  fact,  the  IgA  was  noted
o  be  increased.  A  more  recently  discovered  mechanism  in
atients  infected  with  mycobacterium  describes  the  partic-
pation  of  a  signaling  system  known  as  SLAM-SAP  (signaling
ymphocyte  activation  molecule)  present  in  the  membrane
f  B  and  T  lymphocytes.  SLAM-SAP  triggers  intracellular  sig-
als  with  several  responses;  among  these,  a  discharge  in  IgA
roduction,  such  as  might  have  been  in  this  case.11 This  work
roup  previously  reported  another  case,  but  it  was  asso-
iated  with  cytomegalovirus  in  a bone  marrow  transplant
atient.12
Diagnosis  of  HLH  is  the  ﬁrst  critical  step  for  treatment
uccess.  The  earlier  it  is  begun,  the  less  tissue  damage
nd  less  risk  of  multiple  organ  failure,  which  favors  the
esponse  to  the  HLH-04  treatment.13,14 Participation  of  the
ICU  and  the  supportive  care  provided  play  a  fundamental
ole.
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